FDA Approves First RAS-Targeted Therapy for Metastatic Pancreatic Cancer
Here's what it means for you.
This breakthrough in cancer treatment could reshape patient care and insurance dynamics in oncology.
What happened
The FDA approved daraxonrasib (Rasonque) for adults with metastatic pancreatic adenocarcinoma on August 26, 2026.
The Context
- First of its kind: This is the inaugural RAS-targeted therapy for metastatic pancreatic cancer, addressing a critical treatment gap.
- Survival rates: The pivotal trial demonstrated a median overall survival of 13.2 months, significantly higher than the 6.7 months offered by traditional chemotherapy.
- Expanded access: Prior to approval, over 2,000 patients gained early access through an expanded program initiated by Revolution Medicines.
The Number
— This figure represents the median overall survival with daraxonrasib, highlighting a substantial improvement over existing treatments and emphasizing the need for innovative therapies in oncology.
Takeaway
The approval of daraxonrasib is poised to transform treatment protocols for metastatic pancreatic cancer, with implications for patient outcomes and pharmaceutical revenues.
Conservative-leaning coverage of current events.
"Fox News is a highly influential conservative news outlet known for right-leaning political commentary and coverage."
— A47 Editor
FDA approves once-daily pill for deadly cancer after patients' survival rates nearly double
The FDA has approved Rasonque, a once-daily pill developed by Revolution Medicines, targeting the RAS protein responsible for 95% of pancreatic adenocarcinoma cases. This approval comes after clinical trials showed that patients' survival rates nearl...
Capitol Hill news, legislation, and policy insight.
"The Hill specializes in U.S. politics and policy, with a focus on Capitol Hill developments and a reputation for insider reporting."
— A47 Editor
FDA approves groundbreaking new pancreatic cancer drug
The Food and Drug Administration (FDA) has approved daraxonrasib, a new once-daily pill for advanced pancreatic cancer, branded as Rasonque, providing a new treatment option for patients who have previously undergone other therapies. This approval ma...
Tech startup news, programming trends, and discussions shared by the developer community.
"Hacker News is a community-driven source highlighting influential tech discussions, startup launches, and programming insights."
— A47 Editor
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
The FDA has approved a groundbreaking targeted therapy for metastatic pancreatic cancer, marking a significant advancement in treatment options for this challenging disease. This approval represents a pivotal moment in the fight against pancreatic ca...
Health trends, medical research, and fitness reporting.
"The New York Times is a globally recognized newspaper offering authoritative reporting with a center-left editorial stance."
— A47 Editor
F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
The U.S. Food and Drug Administration (F.D.A.) has approved daraxonrasib, a groundbreaking drug for pancreatic cancer, which has demonstrated the ability to significantly extend patient survival, with trial results showing that patients lived twice a...
Markets, economy, and company analysis from NYT’s business desk.
"The New York Times is a globally recognized newspaper offering authoritative reporting with a center-left editorial stance."
— A47 Editor
F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
The U.S. Food and Drug Administration (F.D.A.) has approved daraxonrasib, a groundbreaking drug for pancreatic cancer, which has demonstrated the ability to significantly extend patient survival, with trial results showing that patients lived twice a...
Scientific research, space, environment, and health coverage.
"The New York Times is a globally recognized newspaper offering authoritative reporting with a center-left editorial stance."
— A47 Editor
F.D.A. Approves the Drug Daraxonrasib That’s Poised to Transform Pancreatic Cancer
The U.S. Food and Drug Administration (F.D.A.) has approved daraxonrasib, a groundbreaking drug for pancreatic cancer, which has demonstrated the ability to significantly extend patient survival, with trial results showing that patients lived twice a...